Home＞REGULATORY
Time Has Arrived to Discuss Formularies at Medical Institutions: MHLW Official(May.23.2017)
Katsuaki Ura, deputy director of the Medical Economics Division |
Katsuaki Ura, deputy director of the Medical Economics Division of the Ministry of Health, Labor and Welfare’s (MHLW) Health Insurance Bureau, said on May 20 that “it’s time to begin discussing formularies (lists of recommended drugs) taking a number of factors into account including cost.” He said he looks forward to discussions on introducing formularies at hospitals ...
(LOG IN FOR FULL STORY)
-
- Expert Cautions against Hasty Discussions on Cost Effective Assessments Apr.20
- Biosimilar Use Essential to Sustain Universal Health Coverage: Society President Apr.19
-
Physicians Association Initiates Large-Scale Study to Directly Compare DPP-4 Inhibitors to SGLT2 Inhibitors, Determine “Optimal Patients” for Each
Apr.19
-
Lynparza Desirable for Use in Early-Stage Maintenance Therapy: Jikei Univ. Prof.
Apr.02
-
Atherosclerosis Society Issues Statement on Use of PCSK9 Inhibitors, Recommending for Patients with FH, Secondary Prevention in High-Risk Patients
Mar.06
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says(Apr.20)
- Expert Cautions against Hasty Discussions on Cost Effective Assessments(Apr.20)
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
